Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.73 |
| ▸ | BRD2 | P25440 | 1/20 | 0.73 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.73 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 3/20 | 0.62 |
| ▸ | CNR2 | P34972 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411779 | 0.85 | BRD4 (1.00) | BRD4BRD2BRD3BRDTSMN1; SMN2 | |
| SCHEMBL13115612 | 0.82 | BRD4 (1.00) | BRD4BRD2BRD3BRDTSMN1; SMN2 | |
| SCHEMBL1137191 | 0.82 | BRD4 (0.70) | BRD4BRD2BRD3BRDTSMN1; SMN2 | |
| SCHEMBL13101588 | 0.81 | BRD4 (0.73) | BRD4BRD2BRD3BRDTSMN1; SMN2 | |
| SCHEMBL31653868 | 0.81 | BRD4 (0.78) | BRD4BRD2BRD3BRDTSMN1; SMN2 | |
| SCHEMBL12376644 | 0.81 | BRD4 (0.57) | BRD4BRD2BRD3BRDTSMN1; SMN2 | |
| SCHEMBL12561624 | 0.80 | BRD4 (0.71) | BRD4BRD2BRD3BRDTSMN1; SMN2 | |
| SCHEMBL1137531 | 0.79 | BRD4 (0.70) | BRD4BRD2BRD3BRDTSMN1; SMN2 | |
| SCHEMBL2621674 | 0.79 | BRD4 (0.74) | BRD4BRD2BRD3BRDTSMN1; SMN2 | |
| SCHEMBL4991600 | 0.78 | BRD4 (0.59) | BRD4BRD2BRD3BRDTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | BRD4 4102/4885BRD2 3344/4885BRD3 4182/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | BRD4 3330/4885BRD2 3753/4885BRD3 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.